Wolfe Research Backs ACAD Stock with 28% Upside Potential and Outperform Rating

Wolfe Research rolled out coverage on ACAD (ACADIA Pharmaceuticals) on February 24, 2026, with an optimistic stance. According to research compiled by Fintel, the firm’s analysts see substantial appreciation potential ahead for the pharmaceutical company’s shares, setting the stage for what could be a meaningful rally for investors.

ACAD Valuation Sits at $31.73—Here’s What Analysts Are Forecasting

The average one-year price target for ACAD stands at $31.73 per share as of early February 2026. This represents a 28.30% climb from the stock’s closing price of $24.73, suggesting meaningful upside if the consensus holds. Analyst estimates for ACAD range widely, from a conservative $17.17 to an optimistic $42.00, reflecting varying views on the company’s trajectory.

However, there’s a complexity beneath the surface. ACADIA Pharmaceuticals’ projected annual revenue is expected to decline by 15.49% to $885 million, while non-GAAP earnings per share are forecast at zero. This revenue headwind presents a challenge that investors need to monitor closely, even as analysts maintain their bullish stance on ACAD.

Institutional Positioning Shows Mixed Signals But Growing Conviction

The institutional investor base for ACAD remains substantial, with 565 funds and institutions holding positions. Though this represents a decrease of 108 owners from the previous quarter (a 16.05% drop), the sentiment hasn’t turned negative. The average portfolio weight dedicated to ACAD across all institutional holders is 0.19%, up 0.56% from the prior period—suggesting those who remain are doubling down.

Total institutional share ownership actually declined slightly, falling by 3.88% to 184.3 million shares over three months. Yet the options market reveals encouraging dynamics: the put/call ratio for ACAD stands at 0.91, a signal that traders are leaning bullish and anticipating further strength.

Major Players Are Increasing Stakes in ACAD Despite Challenges

Several heavyweight institutions have been adjusting their ACAD positions. Baker Bros. Advisors maintains its dominant 42.9 million share stake, representing 25.36% ownership with no changes in the latest quarter. Meanwhile, newer momentum is building elsewhere.

Point72 Asset Management dramatically increased its holdings, raising its ACAD position by 56% from the prior quarter—jumping from 1.5 million to 3.4 million shares. The firm also boosted its portfolio allocation to ACAD by 90%, signaling serious conviction. This aggressive move by one of Wall Street’s most prominent managers could signal growing confidence in ACAD’s near-term prospects.

Similarly, Vanguard’s Total Stock Market Index Fund added shares, increasing its ACAD position by 2% to 4 million shares while raising portfolio allocation by 18%. The iShares Core S&P Small-Cap ETF (IJR) shows a nuanced picture—while it reduced share count slightly, it increased portfolio weight by nearly 25%, suggesting a strategic reweighting toward ACAD despite headwinds.

RTW Investments holds 7.1 million shares representing 4.22% ownership, maintaining its position unchanged through the quarter.

What This Positioning Means for ACAD Investors

The combination of Wolfe Research’s coverage initiation, strong price target upside, and aggressive accumulation by sophisticated players like Point72 paints a picture of building institutional conviction around ACAD. While the revenue decline and zero EPS forecast warrant careful monitoring, the market structure and positioning suggest traders are betting on a turnaround narrative or near-term catalyst that could drive the stock toward that $31.73 target.